17 May 2024
17 May 2024
Bayer’s non-hormonal therapy, elinzanetant, reduced the frequency and severity of hot flashes associated with menopause in two Phase III trials.
Keeping high-qualified, experienced clinical trial staff on board plays a crucial role in bringing new drugs to market. Dana Durkan of KPS Life discusses how to avoid fraudulent staff, navigate work from home dynamics, and keep hold of your most valued employees.
The Clinical Trial in a Dish approach mirrors the human immune response and patient diversity.
Elixir reported high rates of clinical success with its LithiX Hertz Contact IVL system at EuroPCR 2024.
Once-weekly insulin efsitora alfa offered non-inferior A1C reduction in the QWINT-2 and QWINT-4 trials.
Sipavibart demonstrated to offer a statistically significant decline in the symptomatic Covid-19 occurrence.
Sotyktu’s safety profile remained consistent over the four years, without any new safety concerns identified.
The ALS space took another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I/II ALSpire trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
